Investor Ideas Adds Biotech Stocks $PZRX, $SRRA, $SBBP, $SYN
ALSEN.PA, ALVMG.PA, ALPHA.PA; OCC.AX, RHS.AX, VBS.AX; RLM.L, SCLP.L; WNT.ST, XBRANE.ST, OV.ST; 115180.KQ, 019170.KS; SLV.W
Mining, Energy and Tech Stocks also Updated-New Payments & Fintech Section added to Tech Stocks List
Point Roberts, WA and Delta, BC - September 1, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week's additions to its global stock directories in biotech, mining, energy, and tech.
Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector. Listings for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.
The newest biotech companies are trading on markets throughout North America, Asia and Europe and include both life sciences and pharmaceutical companies which are treating a variety of diseases and conditions using a vast array of methods; from research and drug treatments to therapeutics and the latest in cell therapies.
The latest mining companies are all TSX Venture listed and are involved in the exploration of precious metals and rare earth elements.
Advantagewon Oil Corp. (CSE: AOC), is the newest energy company to be listed on the Oil and Gas Stocks List and is a Canadian-based company with operations in Texas.
And finally, Investorideas has upgraded and updated our Technology Stocks List by combining two sub-sectors ‘Mobile Payment Stocks’ and ‘Money Transfer & Payment Processing Stocks’ into the newly named sub-sector ‘Payments & Fintech Stocks’.
Added to this new sector are the payment processing company Global Payout, Inc. (OTC: GOHE), cloud computing company Pure Storage, Inc. (NYSE: PSTG) and financial software services company, SS&C Technologies Holdings, Inc. (NasdaqGS SSNC).
Visit http://www.investorideas.com/TSS/stock_list.asp for full Payments & Fintech Stocks list.
New Biotech Companies Added to Investorideas directory:
Orthocell Ltd (ASX: OCC.AX) is an Australian regenerative medicine company dedicated to restoring mobility and regenerating soft tissue. Founded in 2006, Orthocell provides new approaches to the regeneration of tendon, cartilage and the repair of soft tissue injuries. Orthocell’s Ortho-ATI® therapy is the first autologous cell therapy for tendon and ligament repair and regeneration licensed by a regulatory authority in the major markets of Australia, New Zealand, the USA, Europe, China and Japan. Ortho-ATI® clinical trials and case studies have demonstrated significant pain reduction and functional improvement in a range of different tendons including, gluteal and Extensor Carpi Radialis Brevis (ECRB) (tennis elbow) tendons.
Pharnext (EURONEXT: ALPHA.PA) is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of
Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Oncology Venture ApS (Stockholm: OV.ST) is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP™) technology in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP™ and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis® for breast cancer in collaboration with Cadila Pharmaceuticals; Irofulven developed from a fungus for prostate cancer; and APO010 – an immuno-oncology product for multiple myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US-based company focusing on precision medicine for women’s cancers with a pipeline of three promising Phase 2 product candidates, and Danish OV-SPV 2 which will test and potentially develop the Novartis small molecule kinase inhibitor. Oncology Venture currently owns 92% of 2X Oncology Inc. and 40% of OV-SPV2 ApS.
Qurient Co. Ltd. (Korea:115180.KQ) is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.
PhaseRx, Inc. (NasdaqCM:PZRX) is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle.
Realm Therapeutics Plc (LSE:RLM.L) is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
RHS Limited (ASX: RHS.AX) develops and markets biotechnology technologies primarily in Australia. Its lead products include EmbryoCellect, a preimplantation genetic screening solution; and DOPlif, a whole genome amplification kit.
Scancell Holdings plc (LSE: SCLP.L) is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody® and Moditope® platforms. The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to 'reject' or kill the growing tumour.
Synthetic Biologics, Inc. (NYSE: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).
Selvita S.A.(Warsaw:SLV) is a drug discovery company, developing breakthrough therapies in the area of oncology. The company’s most advanced program, SEL24, has been licensed to Menarini Group and is currently in Phase I studies in AML. Other projects include SEL120, a first-in-class small molecule inhibitor of CDK8 in preclinical studies, several drug discovery platforms in immunooncology, immunometabolism and cancer metabolism, as well as epigenetics, performed independently or in collaboration with global pharma and biotech companies. Selvita also offers a wide range of integrated drug discovery services, helping biotech and pharma partners discover and develop new drugs. The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Merck, H3 Biomedicine, Nodthera Therapeutics/Epidarex Capital and Menarini Group. The company was established in 2007 and currently employs over 400 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow with second research site in Poznan, Poland and international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK.
Sensorion (EURONEXT:ALSEN.PA) is focused on addressing the treatment needs of millions of patients with debilitating inner ear disorders having limited treatment options. We are committed to delivering break-through, life-transforming therapeutics that improve patients’ quality of life. The drugs that we research and evaluate give us a head start in meeting the unmet medical needs of the significant inner ear market.
Shin poong Pharm. Co., Ltd (Korea:o19170.KS) manufactures and sells pharmaceutical products in South Korea. It offers cardiovascular, anti-cancer, psychoneurotic, antirheumatic, antihistamine, and benign prostatic hyperplasia drugs, as well as antibiotics, antiulcerants, anti-diabetics, antifungal and antiviral agents, and trichogens.
Sierra Oncology (NasdaqGM:SRRA) Formerly ProNAi Therapeutics - is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. Our lead drug candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DDR network. SRA737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer:
Strongbridge Biopharma plc (NasdaqGS:SBBP) is a commercial-stage global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency.
Vectus Biosystems Limited (ASX: VBS.AX) is a drug discovery and development company based in North Ryde, Sydney. Using its platform technology, Vectus has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties.
Visiomed Group (EURONEXT: ALVMG.PA) is a company that specializes in next-generation medical electronics. The laboratory develops and markets innovative healthcare products in the promising areas of self-diagnosis for medical use and well-being. VISIOMED is also the inventor of the ThermoFlash®, the 1st contactless medical infrared thermometer. VISIOMED products combine innovation, technology and design to non-drug prevention and treatment solutions focusing on simplicity, comfort and well-being for users. In 2014, VISIOMED GROUP announced the launch of its "BewellConnect®" range of connected healthcare
products, thus becoming the 1st medical electronics laboratory to penetrate the very promising market of the Internet of Things (IoT).
WntResearch (Stockholm: WNT.ST) is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells' ability to relocate and spread in the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastases. The need for a specific treatment to counteract metastasis is therefore in high demand. WntResearch's most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells' mobility and thereby counteract the occurrence of metastases. The results from a completed phase 1 study show a favourable safety and pharmacokinetic profile, as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer of the colon, prostate and breast.
Xbrane Biopharma (Stockholm: XBRANE.ST) is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy.
New Mining Companies:
Canada Rare Earth Corp. (TSXV: LL.V) is developing an international integrated business network within the global rare earth industry. Our immediate key focus is to generate revenues and positive cash flow from a variety of profit centers in the rare earth production and sales chain by sourcing, adding value and selling rare earths in all stages and forms. We are in the process of establishing our own mining, concentrating and refinery capabilities in addition to working with affiliated and third party organizations.
Rainy Mountain Royalty Corp. (TSXV: RMO.V; FSE: EK7N) is a Canadian based exploration company exploring for copper, zinc, nickel and precious metals in northwestern Ontario. The Company's focus at this time is shear hosted gold deposits and base metals with associated gold and silver credits.
Sojourn Exploration Inc. (TSX: SOJ.V) is unlocking the potential of the famed and mineral-rich Golden Triangle. By adopting a "prospect generator" exploration finance model and partnering with a technical and pioneering geologist–20 plus years working in northwestern BC’s tough and steep typography, Sojourn is well positioned to advance drilling and exploration of its newly optioned Willoughby and Oweegee Dome properties.
New Energy Companies:
Advantagewon Oil Corp. (CSE: AOC) is a Toronto-based Oil Company with a focus on development opportunities in the State of Texas. Advantagewon currently owns two properties in the State of Texas: the Saratoga property located in Hardin County, Texas; and the LaVernia property located in Guadalupe County, Texas.
New Tech Companies:
Global Payout, Inc. (OTC: GOHE) is a processor of payments for corporate clients and their customers, members, employees, contractors, agents and suppliers worldwide and has access to processing and payment delivery platforms and networks. Global Payout is a Program Manager providing both project management advisory services and direct account provisioning systems that can be offered through Global's eWallet platforms, digital currency management, and prepaid debit card issuing bank programs located throughout the world. This enables end-users of the platform to maximize an expanded suite of financial services and minimize operational costs through integration of state-of- the-art FinTech applications and platforms.
Pure Storage, Inc. (NYSE: PSTG) helps companies push the boundaries of what's possible. Pure's end-to-end data platform - including FlashArray, FlashBlade and our converged offering with Cisco, FlashStack – is powered by innovative software that's cloud-connected for management from anywhere on a mobile device and supported by the Evergreen business model. The company's all-flash based technology, combined with its customer-friendly business model, drives business and IT transformation with solutions that are effortless, efficient and evergreen. With Pure's industry leading Satmetrix-certified NPS score of 83.7, Pure customers are some of the happiest in the world, and include organizations of all sizes, across an ever-expanding range of industries.
SS&C Technologies Holdings, Inc. (NasdaqGS SSNC) is a global provider of investment and financial software-enabled services and software for the global financial services industry. Founded in 1986, SS&C is headquartered in Windsor, Connecticut and has offices around the world. Some 11,000 financial services organizations, from the world's largest institutions to local firms, manage and account for their investments using SS&C's products and services.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Ideas
Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.
The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!
Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp
Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.